Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OAX Equities |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2021-03-29 08:02:23
Oslo, Norway (29 March 2021) -
Reference is made to the offer document dated 8 March 2021 (the "Offer
Document") for the recommended voluntary offer by Compagnie des Levures Lesaffre
(the "Offeror") to acquire all outstanding shares in NattoPharma ASA
("NattoPharma" or the "Company") against a consideration in cash of NOK 35 per
share (the "Offer"), and further reference is made to the stock exchange
announcement dated 23 March 2021 in which the Offeror announced that the closing
conditions "Minimum Acceptance" and "Regulatory Approval" are considered to be
fulfilled.
All of the Company's option holders, representing all of the outstanding
1,200,850 options in the Company (the "Company Options"), have irrevocably
committed to exercise the Company Options to subscribe for Shares in the Company
and to sell such Shares to the Offeror on the same terms and conditions as the
Offer.
Based on the authorization granted at the annual general meeting of NattoPharma
on June 19, 2020, the Board of Directors of NattoPharma has therefore resolved a
share issue of 1,200,850 new shares, each with a nominal value of NOK 3 per
share.
The share capital increase has been registered and the Company's new share
capital is NOK 63,132,849 divided into 21,044,283 registered shares each with a
nominal value of NOK 3.00.
***
For more information, please contact:
Robert Schrama, CFO
E-mail: robert.schrama@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities